Novartis to Invest $95 Mil. in Korea Cancer Radiotherapy Supply Chain
3 Articles
3 Articles
Swiss pharmaceutical company Novartis is investing approximately 140 billion won to build a domestic ecosystem for radioligand therapeutics (RLTs). The plan is to establish domestic production facilities and increase the number of hospitals capable of providing treatment to improve patient accessibility, while simultaneously fostering Korea as a hub for RLT research and development. On the 21st, at the Novotel Ambassador Hotel in Yongsan, Seoul,…
Novartis to invest $95 mil. in Korea cancer radiotherapy supply chain
Swiss pharmaceutical giant Novartis is set to invest about 140 billion won ($95 million) to build a domestic radioligand therapy (RLT) ecosystem in Korea, covering research, production and treatment. Health and Welfare Minister Jeong Eun-kyeong and Novartis Asia-Pacific, Middle East and Africa President Judith Love signed a memorandum of understanding on the plan in Yongsan District, Seoul, Tuesday. RLT is a treatment that uses a radioactive sub…
(Seoul = Yonhap News) Reporter Kim Jan-di = The Ministry of Health and Welfare is partnering with multinational pharmaceutical companies to establish a domestic supply chain for radiopharmaceuticals.
Coverage Details
Bias Distribution
- 67% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
